PMID- 38495948
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240319
IS  - 1179-5514 (Print)
IS  - 1179-5514 (Electronic)
IS  - 1179-5514 (Linking)
VI  - 17
DP  - 2024
TI  - Safety and Effectiveness of Sodium-Glucose Co-transporter 2 Inhibitors on 
      Glycemic Control in Patients with Type 2 Diabetes Mellitus Fasting during 
      Ramadan: A Review.
PG  - 11795514241238058
LID - 10.1177/11795514241238058 [doi]
LID - 11795514241238058
AB  - This review evaluates the current evidence on the safety and efficacy of 
      sodium-glucose cotransporter 2 (SGLT2) inhibitors for patients with type 2 
      diabetes mellitus (T2DM) fasting during Ramadan. All studies included in the 
      review were conducted in Asia and the Middle East. Overall, the evidence suggests 
      that SGLT2 inhibitors are a safe and effective treatment option for most T2DM 
      patients fasting during Ramadan. The average incidence of symptomatic 
      hypoglycemia is 12.5%, but ranges from 0.7% to 27%, depending on the study 
      population and concomitant use of other medications. The risk of hypoglycemia is 
      increased when SGLT2 inhibitors are used in combination with insulin and/or 
      sulfonylureas. Therefore, patients taking SGLT2 inhibitors in combination with 
      insulin and/or sulfonylureas can take steps to mitigate this risk, such as having 
      their insulin and/or sulfonylurea doses adjusted and being closely monitored for 
      hypoglycemia. Patients taking SGLT2 inhibitors may be at increased risk of 
      dehydration. To mitigate the risk of dehydration, patients should be advised to 
      consume adequate fluids during the fast-breaking hours. Further research is 
      warranted to validate these findings and extend their applicability to high-risk 
      populations and other regions of the world.
CI  - (c) The Author(s) 2024.
FAU - Nakhleh, Afif
AU  - Nakhleh A
AUID- ORCID: 0000-0003-1206-1516
AD  - Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, Haifa, Israel.
AD  - Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, 
      Haifa, Israel.
AD  - The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
FAU - Mazareeb, Jomana
AU  - Mazareeb J
AD  - Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, Haifa, Israel.
FAU - Darawshi, Said
AU  - Darawshi S
AD  - Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, 
      Haifa, Israel.
FAU - Masri, Amin
AU  - Masri A
AD  - Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, 
      Haifa, Israel.
FAU - Shehadeh, Naim
AU  - Shehadeh N
AD  - Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, Haifa, Israel.
AD  - Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, 
      Haifa, Israel.
AD  - The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240314
PL  - United States
TA  - Clin Med Insights Endocrinol Diabetes
JT  - Clinical medicine insights. Endocrinology and diabetes
JID - 101578235
PMC - PMC10943741
OAB - Safety and effectiveness of sodium-glucose co-transporter 2 inhibitors on 
      glycemic control in patients with type 2 diabetes mellitus fasting during 
      Ramadan: a review This review delves into the existing evidence regarding the 
      safety and efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors for 
      patients with type 2 diabetes mellitus (T2DM) who observe Ramadan fasting. The 
      studies reviewed were conducted exclusively in Asia and the Middle East. Overall, 
      the gathered evidence suggests that SGLT2 inhibitors constitute a safe and 
      effective treatment option for most T2DM patients fasting during Ramadan. While a 
      slightly elevated risk of dehydration compared to other medications may exist, 
      this is generally well-tolerated. To mitigate the risk of dehydration, patients 
      should be advised to consume adequate fluids during the fast-breaking hours. 
      However, further research is warranted to validate these findings and extend 
      their applicability to high-risk populations and other world regions.
OABL- eng
OTO - NOTNLM
OT  - Ramadan
OT  - SGLT2 inhibitors
OT  - fasting
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2024/03/18 06:43
MHDA- 2024/03/18 06:44
PMCR- 2024/03/14
CRDT- 2024/03/18 04:30
PHST- 2023/11/13 00:00 [received]
PHST- 2024/02/13 00:00 [accepted]
PHST- 2024/03/18 06:44 [medline]
PHST- 2024/03/18 06:43 [pubmed]
PHST- 2024/03/18 04:30 [entrez]
PHST- 2024/03/14 00:00 [pmc-release]
AID - 10.1177_11795514241238058 [pii]
AID - 10.1177/11795514241238058 [doi]
PST - epublish
SO  - Clin Med Insights Endocrinol Diabetes. 2024 Mar 14;17:11795514241238058. doi: 
      10.1177/11795514241238058. eCollection 2024.